Assessment of Efficacy of Antifungals against Aspergillus fumigatus: Value of Real-Time Bioluminescence Imaging
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aspergillus fumigatus causes life-threatening infections, especially in immunocompromised patients. Common drugs for therapy of aspergillosis are polyenes, azoles, and echinocandins. However, despite in vitro efficacy of these antifungals, treatment failure is frequently observed. In this study, we established bioluminescence imaging to monitor drug efficacy under in vitro and in vivo conditions.In vitro assays confirmed the effectiveness of liposomal amphotericin B, voriconazole, and anidulafungin. Liposomal amphotericin B and voriconazole were fungicidal, whereas anidulafungin allowed initial germination of conidia that stopped elongation but allowed the conidia to remain viable.In vivo studies were performed with a leukopenic murine model. Mice were challenged by intranasal instillation with a bioluminescent reporter strain (5 × 10 5 and 2.5 × 10 5 conidia), and therapy efficacies of liposomal amphotericin B, voriconazole, and anidulafungin were monitored. For monotherapy, the highest treatment efficacy was observed with liposomal amphotericin B, whereas the efficacies of voriconazole and anidulafungin were strongly dependent on the infectious dose. When therapy efficacy was studied with different drug combinations, all combinations improved the rate of treatment success compared to that with monotherapy. One hundred percent survival was obtained for treatment with a combination of liposomal amphotericin B and anidulafungin, which prevented not only pulmonary infections but also infections of the sinus. In conclusion, combination therapy increases treatment success, at least in the murine infection model. In addition, our novel approach based on real-time imaging enables in vivo monitoring of drug efficacy in different organs during therapy of invasive aspergillosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antifungal agents: mechanisms of action
Odds, F. C., Brown, A. J. P., & Gow, N. A. R. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00117-3 · Cited by 1,202 · cited 1×
“However, microcolonies formed on the plates and were also observed in the microdilution test, which is in agreement with a fungistatic rather than fungicidal effect of this drug (27).”
ResultEfficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 1×
“Liposomal amphotericin B (32, 33) and voriconazole (34–36) are common drugs in prophylactic use to prevent fungal infections in high-risk patients, although treatment failure and breakthrough of invasive fungal infections have been observed (2, 37, 38).”
BackgroundInvasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791 · cited 1×
“A review of 595 patients with proven or probable invasive aspergillosis identified a high rate of treatment failure for a wide range of antifungal drugs (36%), with only 27% of treated patients demonstrating a complete response to treatment (1).”
BackgroundCombination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
Balloy, V., Huerre, M., Latgé, J.-P., & Chignard, M. (2005) · Infection and Immunity · doi:10.1128/iai.73.1.494-503.2005 · Cited by 231
Herbrecht, R., Maertens, J., Baila, L., Aoun, M., Heinz, W., Martino, R., Schwartz, S., Ullmann, A. J., Meert, L., Paesmans, M., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.334 · Cited by 149 · cited 1×
“In addition, each of the echinocandins shows activity without significant toxicity in therapy of invasive candidiasis (5, 6).”
BackgroundCordonnier, C., Rovira, M., Maertens, J., Olavarria, E., Faucher, C., Bilger, K., Pigneux, A., Cornely, O. A., Ullmann, A. J., Bofarull, R. M., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.020073 · Cited by 137
Application of Bioluminescence Imaging for In Vivo Monitoring of Fungal Infections
Brock, M. (2012) · International Journal of Microbiology · doi:10.1155/2012/956794 · Cited by 42
Self-citation
Cited by
Methods for in vitro evaluating antimicrobial activity: A review
Balouiri, M., Sadiki, M., & Ibnsouda, S. K. (2016) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2015.11.005 · Cited by 8,044
Diverse Regulation of the CreA Carbon Catabolite Repressor in Aspergillus nidulans
Ries, L. N. A., Beattie, S. R., Espeso, E. A., Cramer, R. A., & Goldman, G. H. (2016) · Genetics · doi:10.1534/genetics.116.187872 · Cited by 162
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
“…(Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et al. 2008; Vallor et al. 2008; Wiederhold et al. 2008; Walsh et al. 2009; Howard et al. 2011; Lengerova et al. 2012; Galiger et al. 2013).”
BackgroundJacobsen, I. D., Lüttich, A., Kurzai, O., Hube, B., & Brock, M. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku198 · Cited by 73
Self-citationDesoubeaux, G., & Cray, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00841 · Cited by 55
“Some A. fumigatus strains were selected for their very specific features like bioluminescent AfC3 (Brock et al., 2008; IbrahimGranet et al., 2010; Fekkar et al., 2012; Jouvion et al., 2012; Morisse et al., 2012) or Af 2/7/1 (Galiger et al., 2013; Savers et al., 2016).”
Background
Metadata
- Authors
- Galiger, C., Brock, M., Jouvion, G., Savers, A., Parlato, M., & Ibrahim-Granet, O.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-07
- Volume
- 57
- Issue
- 7
- Pages
- 3046-3059
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2170997336
- Cited by
- 59
- References
- 8
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of Efficacy of Antifungals against Aspergillus fumigatus: Value of Real-Time Bioluminescence Imaging. https://app.cochat.ai/papers/10.1128/aac.01660-12
- The paper
- Galiger, C., Brock, M., Jouvion, G., Savers, A., Parlato, M., & Ibrahim-Granet, O. (2013). Assessment of Efficacy of Antifungals against Aspergillus fumigatus: Value of Real-Time Bioluminescence Imaging. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01660-12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.